Here is a data-driven look at Glaxosmithkline Pharmaceuticals Ltd. (GLAXO), covering financial performance, valuation, and shareholding trends.
Glaxo Pharma Revenue Trend
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹3,822 Cr in FY2026, a 1.9% increase from ₹3,749 Cr in FY2025.
A 3.1% CAGR over 13 years is underwhelming. In real terms, Glaxosmithkline Pharmaceuticals Ltd.'s revenue has barely grown from ₹2,563 Cr to ₹3,822 Cr.
At ₹3,822 Cr in annual revenue, Glaxosmithkline Pharmaceuticals Ltd. is one of the mid-sized players in the pharmaceuticals space.
The consistency stands out: 6 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹3,822 Cr | +1.9% |
| FY2025 | ₹3,749 Cr | +8.6% |
| FY2024 | ₹3,454 Cr | +4.4% |
| FY2021 | ₹3,309 Cr | +2.6% |
| FY2020 | ₹3,224 Cr | — |
View Glaxosmithkline Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Glaxo Pharma Profitability
Year-over-year, net profit grew 11.7% from ₹928 Cr to ₹1,036 Cr in FY2026 for Glaxosmithkline Pharmaceuticals Ltd..
The company squeezed out better margins in FY2026, with net margin at 27.1% versus 24.7% in FY2025.
At ₹61.15 per share (diluted), FY2026 earnings were up year-over-year from ₹54.76.
Is Glaxo Pharma Undervalued
Glaxosmithkline Pharmaceuticals Ltd. shares are currently trading at ₹2,662.30.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Glaxo Pharma Shareholding Pattern
Promoters continue to hold 75.0% of the company, unchanged over recent quarters.
Foreign institutional investors (FIIs) held 4.8% as of June 2026, down from 4.8% a year ago.
Domestic institutional investors (DIIs) held 7.8% as of June 2026, up from 7.8% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 75.0% | 4.8% | 7.8% | 12.4% |
| Mar 2026 | 75.0% | 4.6% | 7.7% | 12.7% |
| Dec 2025 | 75.0% | 4.6% | 7.7% | 12.7% |
| Sep 2025 | 75.0% | 4.8% | 7.8% | 12.4% |
Track quarterly shareholding changes for Glaxosmithkline Pharmaceuticals Ltd. →
Glaxo Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹43.24B (up 5.3% YoY from ₹41.08B).
Top categories: Cash & ST Investments (57.7%), Other Assets (18.9%), Inventories (10.6%).
Of the ₹43.24B in liabilities and equity, 52.4% is shareholder equity, 0.8% is interest-bearing debt, and 46.8% is operating liabilities. Over the year, debt is up 234.4% and equity is up 16.2%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 24.93B |
| Receivables | 2.73B |
| Inventories | 4.58B |
| Property, Plant & Equipment | 2.75B |
| Investments | 8.67M |
| Intangibles & Goodwill | 65.56M |
| Other Assets | 8.18B |
| Category | Value |
|---|---|
| Equity | 22.67B |
| Short-term Debt | 159.99M |
| Long-term Debt | 172.73M |
| Trade Payables | 5.70B |
| Other Liabilities | 14.53B |
What Stands Out About Glaxo Pharma
Bringing the key threads together for Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) as a pharmaceuticals investment opportunity.
Revenue of ₹3,822 Cr in FY2026, up 1.9% year-over-year.
Long-term revenue has been compounding at 3.1% annually over 13 years.
The company is profitable, with a net margin of 27.1% and net income of ₹1,036 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Glaxosmithkline Pharmaceuticals Ltd..